Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Aztreonam-Avibactam in Severe Renal Impairment
NCT04486625Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2020
- Primary completion
- Sep 2021
- Modality
- Covalent Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of aztreonam + avibactam in gram-negative bacterial infections, Intra-abdominal infection (IAI), hospital-acquired pneumonia (HAP) and 1 more (2 arms), sponsored by Pfizer. Primary endpoints: Total Daily Area Under the Plasma Concentration-time Profile From Time 0 to 24 Hours at Steady-state of Aztreonam, Maximum Plasma Concentration of Aztreonam at Day 3 and 2 more. Started Aug 2020; status: completed.
02
Drugs
aztreonam + avibactam
03
Conditions
gram-negative bacterial infectionsIntra-abdominal infection (IAI)hospital-acquired pneumonia (HAP)complicated urinary tract infection (cUTI)
Beyond the preview
Go deeper on NCT04486625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04486625.